BlackRock Inc. cut its stake in AstraZeneca plc (NYSE:AZN) by 9.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,377,522 shares of the company’s stock after selling 650,052 shares during the quarter. BlackRock Inc.’s holdings in AstraZeneca were worth $221,300,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of AZN. Russell Investments Group Ltd. raised its holdings in AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after purchasing an additional 1,235,239 shares in the last quarter. Hardman Johnston Global Advisors LLC bought a new position in AstraZeneca in the 4th quarter worth $35,125,000. Sector Gamma AS bought a new position in AstraZeneca in the 3rd quarter worth $25,094,000. Janus Henderson Group PLC raised its holdings in AstraZeneca by 5,754.0% in the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after purchasing an additional 714,187 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in AstraZeneca by 103.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares in the last quarter. Institutional investors and hedge funds own 15.15% of the company’s stock.
AstraZeneca plc (NYSE:AZN) opened at $33.84 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. The stock has a market cap of $84,280.00, a PE ratio of 28.92, a P/E/G ratio of 2.02 and a beta of 0.75. AstraZeneca plc has a 12 month low of $28.43 and a 12 month high of $36.70.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. AstraZeneca’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the business earned $1.21 EPS. analysts anticipate that AstraZeneca plc will post 1.69 earnings per share for the current year.
The firm also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s payout ratio is 117.09%.
Several research analysts have commented on AZN shares. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, January 10th. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 7th. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Leerink Swann restated a “market perform” rating and issued a $36.00 price objective (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, Sanford C. Bernstein upped their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $36.26.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/03/15/blackrock-inc-decreases-holdings-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.